Sanofi annual operating cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sanofi Operating Cash Flow Growth & History (SAN)
Sanofi's operating cash flow was €10.75B for fiscal 2025.
View full Sanofi company overviewSanofi annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €10.75B | €1.67B | +18.38% |
| 2024 | 2024-12-31 | €9.08B | −€1.18B | −11.47% |
| 2023 | 2023-12-31 | €10.26B | −€268.0M | −2.55% |
| 2022 | 2022-12-31 | €10.53B | €4.0M | +0.04% |
| 2021 | 2021-12-31 | €10.52B | €3.10B | +41.84% |
| 2020 | 2020-12-31 | €7.42B | −€297.0M | −3.85% |
| 2019 | 2019-12-31 | €7.71B | €2.17B | +39.08% |
| 2018 | 2018-12-31 | €5.55B | −€1.83B | −24.83% |
| 2017 | 2017-12-31 | €7.38B | −€459.0M | −5.86% |
| 2016 | 2016-12-31 | €7.84B | −€452.0M | −5.45% |
| 2015 | 2015-12-31 | €8.29B | — | — |
Sanofi quarterly operating cash flow
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €2.96B | €1.50B | +102.46% |
| Q1 2026 | 2026-03-31 | €1.68B | — | — |
| Q4 2025 | 2025-12-31 | €3.44B | — | — |
| Q3 2025 | 2025-09-30 | €3.75B | — | — |
| Q2 2025 | 2025-06-30 | €1.46B | — | — |
Sanofi operating cash flow trends
Over the last five fiscal years, Sanofi's operating cash flow increased from €7.42B to €10.75B, a change of €3.33B. The latest reported quarter, Q2 2026, shows €2.96B.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sanofi source filings ↗Community posts
Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basi ...
